Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors.

St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J, Hess P, Jie Lan, Liu S, Riendeau D, Steiner B, Percival MD.

J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):133-45. doi: 10.1177/1470320310392618. Epub 2011 Mar 10.

PMID:
21393355
2.

Trisubstituted ureas as potent and selective mPGES-1 inhibitors.

Chiasson JF, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Giroux A, Guay J, Guiral S, Mancini J, Massé F, Méthot N, Riendeau D, Roy P, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1488-92. doi: 10.1016/j.bmcl.2011.01.006. Epub 2011 Jan 13.

PMID:
21295979
3.

Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.

Wu TY, Juteau H, Ducharme Y, Friesen RW, Guiral S, Dufresne L, Poirier H, Salem M, Riendeau D, Mancini J, Brideau C.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):6978-82. doi: 10.1016/j.bmcl.2010.09.129. Epub 2010 Oct 19.

PMID:
20965723
4.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28.

PMID:
20061146
5.

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors.

Giroux A, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Frenette R, Gagnon M, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5837-41. doi: 10.1016/j.bmcl.2009.08.085. Epub 2009 Aug 28.

PMID:
19748780
6.

MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.

Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D.

J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4.

PMID:
18524979
7.

Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1.

Hétu PO, Ouellet M, Falgueyret JP, Ramachandran C, Robichaud J, Zamboni R, Riendeau D.

Arch Biochem Biophys. 2008 Sep 1;477(1):155-62. doi: 10.1016/j.abb.2008.04.038. Epub 2008 May 6.

PMID:
18498757
8.

In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.

Méthot N, Guay D, Rubin J, Ethier D, Ortega K, Wong S, Normandin D, Beaulieu C, Reddy TJ, Riendeau D, Percival MD.

Mol Pharmacol. 2008 Jun;73(6):1857-65. doi: 10.1124/mol.108.045682. Epub 2008 Mar 6.

PMID:
18326050
9.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2.

PMID:
18276139
10.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. doi: 10.1016/j.bmcl.2007.12.047. Epub 2008 Jan 15.

PMID:
18226527
11.

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.

Côté B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6816-20. Epub 2007 Oct 17.

PMID:
18029174
12.

Effect of cathepsin k inhibitor basicity on in vivo off-target activities.

Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, Duong LT, Pickarski M, Percival MD.

Mol Pharmacol. 2008 Jan;73(1):147-56. Epub 2007 Oct 16.

PMID:
17940194
13.

Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.

Méthot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ, Riendeau D, Percival MD.

J Biol Chem. 2007 Jul 20;282(29):20836-46. Epub 2007 May 29.

14.

Advanced practice: where are you going and how do you get there?

Riendeau D.

Imprint. 2007 Jan;54(1):50-4, 56-7. Review. No abstract available.

PMID:
17378400
15.
16.
17.

Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium.

Kawka DW, Ouellet M, Hétu PO, Singer II, Riendeau D.

Biochim Biophys Acta. 2007 Jan;1771(1):45-54. Epub 2006 Oct 5.

PMID:
17189713
18.

New technology applications: thrombolysis of acute deep vein thrombosis.

Marchigiano G, Riendeau D, Jo Morse C.

Crit Care Nurs Q. 2006 Oct-Dec;29(4):312-23; quiz 324-5. Review.

PMID:
17063098
19.

Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.

Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC, Riendeau D, Audoly LP.

J Pharmacol Exp Ther. 2006 Dec;319(3):1043-50. Epub 2006 Sep 14.

PMID:
16973887
20.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falgueyret JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y.

Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31. Epub 2006 Feb 7.

PMID:
16464579
21.

Identification of a potent and selective non-basic cathepsin K inhibitor.

Li CS, Deschenes D, Desmarais S, Falgueyret JP, Gauthier JY, Kimmel DB, Léger S, Massé F, McGrath ME, McKay DJ, Percival MD, Riendeau D, Rodan SB, Thérien M, Truong VL, Wesolowski G, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1985-9. Epub 2006 Jan 18.

PMID:
16413777
22.

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.

Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Massé F, Riendeau D, Toulmond S, Percival MD.

J Med Chem. 2005 Dec 1;48(24):7535-43.

PMID:
16302795
23.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G.

J Med Chem. 2005 Dec 1;48(24):7520-34.

PMID:
16302794
24.
25.

Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.

Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Méthot N, Rubin J, Friesen RW.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5.

PMID:
15953724
26.

An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells.

Falgueyret JP, Black WC, Cromlish W, Desmarais S, Lamontagne S, Mellon C, Riendeau D, Rodan S, Tawa P, Wesolowski G, Bass KE, Venkatraman S, Percival MD.

Anal Biochem. 2004 Dec 15;335(2):218-27. Erratum in: Anal Biochem. 2005 May 15;340(2):380.

PMID:
15556560
27.
28.

Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.

Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, Méthot N.

J Biol Chem. 2004 May 28;279(22):23229-37. Epub 2004 Mar 11.

29.

Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2.

Riendeau D, Salem M, Styhler A, Ouellet M, Mancini JA, Li CS.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1201-3.

PMID:
14980665
30.

Expression, purification and characterization of recombinant human microsomal PGE2 synthase-1.

Ouellet M, Pen A, Ear PH, Falgueyret JP, LeRiche TG, Mancini JA, Riendeau D, Percival MD.

Adv Exp Med Biol. 2003;525:113-6. No abstract available.

PMID:
12751747
31.
32.

3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

Black WC, Brideau C, Chan CC, Charleson S, Cromlish W, Gordon R, Grimm EL, Hughes G, Leger S, Li CS, Riendeau D, Thérien M, Wang Z, Xu LJ, Prasit P.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1195-8.

PMID:
12643942
33.

Pyridazinones as selective cyclooxygenase-2 inhibitors.

Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Thérien M, Wong E, Prasit P.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):597-600.

PMID:
12639538
34.

Purification and characterization of recombinant microsomal prostaglandin E synthase-1.

Ouellet M, Falgueyret JP, Ear PH, Pen A, Mancini JA, Riendeau D, Percival MD.

Protein Expr Purif. 2002 Dec;26(3):489-95.

PMID:
12460774
35.

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

Leblanc Y, Roy P, Wang Z, Li CS, Chauret N, Nicoll-Griffith DA, Silva JM, Aubin Y, Yergey JA, Chan CC, Riendeau D, Brideau C, Gordon R, Xu L, Webb J, Visco DM, Prasit P.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3317-20.

PMID:
12392741
36.

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.

Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF.

Circulation. 2002 Apr 16;105(15):1816-23.

PMID:
11956125
37.
38.
39.

Urogenital distribution of a mouse membrane-associated prostaglandin E(2) synthase.

Guan Y, Zhang Y, Schneider A, Riendeau D, Mancini JA, Davis L, Kömhoff M, Breyer RM, Breyer MD.

Am J Physiol Renal Physiol. 2001 Dec;281(6):F1173-7.

40.

Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.

Wong E, Huang JQ, Tagari P, Riendeau D.

Atherosclerosis. 2001 Aug;157(2):393-402.

PMID:
11472739
41.

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1059-62.

PMID:
11327589
42.

Mutations of the C-terminal end of cathepsin K affect proenzyme secretion and intracellular maturation.

Claveau D, Riendeau D.

Biochem Biophys Res Commun. 2001 Feb 23;281(2):551-7.

PMID:
11181082
43.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.

J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.

PMID:
11160644
44.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

Falgueyret JP, Oballa RM, Okamoto O, Wesolowski G, Aubin Y, Rydzewski RM, Prasit P, Riendeau D, Rodan SB, Percival MD.

J Med Chem. 2001 Jan 4;44(1):94-104.

PMID:
11141092
45.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).

Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D.

Bioorg Med Chem Lett. 2000 Dec 4;10(23):2683-6.

PMID:
11128651
46.

Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis.

Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D.

J Biol Chem. 2001 Feb 9;276(6):4469-75. Epub 2000 Nov 6.

47.

Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells.

Claveau D, Riendeau D, Mancini JA.

Biochem Pharmacol. 2000 Sep 15;60(6):759-69.

PMID:
10930530
48.
49.

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

Lau CK, Brideau C, Chan CC, Charleson S, Cromlish WA, Ethier D, Gauthier JY, Gordon R, Guay J, Kargman S, Li CS, Prasit P, Riendeau D, Thérien M, Visco DM, Xu L.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3187-92.

PMID:
10576685
50.

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.

Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P.

Bioorg Med Chem Lett. 1999 Nov 15;9(22):3181-6.

PMID:
10576684

Supplemental Content

Loading ...
Support Center